| 0 (0%) | 06-28 18:07 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 30.23 | 1-year : | 30.89 |
| Resists | First : | 25.88 | Second : | 26.45 |
| Pivot price | 25.5  |
|||
| Supports | First : | 24.96 | Second : | 20.77 |
| MAs | MA(5) : | 25.17 |
MA(20) : | 25.64 |
| MA(100) : | 26.16 |
MA(250) : | 26.67 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 13.1 |
D(3) : | 15.6 |
| RSI | RSI(14): 31.2 |
|||
| 52-week | High : | 27.98 | Low : | 24.96 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ RILYP ] has closed above bottom band by 14.7%. Bollinger Bands are 18.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 25.27 - 25.41 | 25.41 - 25.53 |
| Low: | 24.53 - 24.73 | 24.73 - 24.9 |
| Close: | 24.8 - 25.1 | 25.1 - 25.35 |
Thu, 21 Jul 2016
Relypsa (RLYP) Stock Surging on $1.5 Billion Acquisition by Galencia - TheStreet
Tue, 26 Apr 2016
Hedged Relypsa Longs: Consider This Course Correction (NASDAQ:RLYP-DEFUNCT-114642) - Seeking Alpha
Mon, 25 Apr 2016
Relypsa sets up hyperkalemia showdown with AstraZeneca - Fierce Biotech
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0 (%) |
| Shares Short | 6 (K) |
| Shares Short P.Month | 1 (K) |
| EPS | 19.45 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 25.64 |
| Profit Margin | 34.6 % |
| Operating Margin | 46.9 % |
| Return on Assets (ttm) | 15.1 % |
| Return on Equity (ttm) | 74.4 % |
| Qtrly Rev. Growth | 74 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.5 % |
| Operating Cash Flow | -197 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | 1.29 |
| PEG Ratio | 0 |
| Price to Book value | 0.97 |
| Price to Sales | 0 |
| Price to Cash Flow | -0 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | 2022-01-30 |
| Ex-Dividend Date | 2022-01-19 |
|
|
|
|
|
|
|
|
|